PADAGIS US Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PADAGIS US, and when can generic versions of PADAGIS US drugs launch?
PADAGIS US has eighty-eight approved drugs.
There is one US patent protecting PADAGIS US drugs.
There are twenty-two patent family members on PADAGIS US drugs in fourteen countries and one hundred and twenty-three supplementary protection certificates in fifteen countries.
Summary for PADAGIS US
| International Patents: | 22 |
| US Patents: | 1 |
| Tradenames: | 65 |
| Ingredients: | 60 |
| NDAs: | 88 |
Drugs and US Patents for PADAGIS US
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Us | HYDROMORPHONE HYDROCHLORIDE | hydromorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 204278-002 | Apr 6, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Us | POTASSIUM CHLORIDE | potassium chloride | TABLET, EXTENDED RELEASE;ORAL | 205993-002 | Nov 5, 2015 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Us | CLINDETS | clindamycin phosphate | SWAB;TOPICAL | 064136-001 | Sep 30, 1996 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Us | TRETINOIN | tretinoin | CREAM;TOPICAL | 075264-001 | Dec 24, 1998 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Us | DESONIDE | desonide | OINTMENT;TOPICAL | 017426-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Padagis Us | BACITRACIN | bacitracin | OINTMENT;OPHTHALMIC | 061212-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PADAGIS US
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Padagis Us | EVAMIST | estradiol | SPRAY;TRANSDERMAL | 022014-001 | Jul 27, 2007 | 6,923,983 | ⤷ Sign Up |
| Padagis Us | EVAMIST | estradiol | SPRAY;TRANSDERMAL | 022014-001 | Jul 27, 2007 | 6,818,226 | ⤷ Sign Up |
| Padagis Us | ENTOCORT EC | budesonide | CAPSULE, DELAYED RELEASE;ORAL | 021324-001 | Oct 2, 2001 | 5,643,602*PED | ⤷ Sign Up |
| Padagis Us | BUTOCONAZOLE NITRATE | butoconazole nitrate | CREAM;VAGINAL | 019881-001 | Feb 7, 1997 | 4,551,148 | ⤷ Sign Up |
| Padagis Us | BUTOCONAZOLE NITRATE | butoconazole nitrate | CREAM;VAGINAL | 019881-001 | Feb 7, 1997 | 5,266,329 | ⤷ Sign Up |
| Padagis Us | CLINDESSE | clindamycin phosphate | CREAM;VAGINAL | 050793-001 | Nov 30, 2004 | 5,993,856 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PADAGIS US drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Vaginal Cream | 2% | ➤ Subscribe | 2015-02-05 |
| ➤ Subscribe | Enteric Coated Capsules | 3 mg | ➤ Subscribe | 2008-02-01 |
International Patents for PADAGIS US Drugs
Supplementary Protection Certificates for PADAGIS US Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2957286 | 300962 | Netherlands | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170721 |
| 2957286 | 2018C/047 | Belgium | ⤷ Sign Up | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 1380301 | 2009C/007 | Belgium | ⤷ Sign Up | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| 2782584 | 301153 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406 |
| 0733366 | SPC/GB98/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| 2435024 | SPC/GB21/029 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
